Table 1.
Hydroxychloroquine + Azithromycin n = 152 |
Hydroxychloroquine n = 152 | Placebo n = 152 |
|
---|---|---|---|
Male sex | 150 (98·7%) | 149 (98·0%) | 150 (98·7%) |
Age (years) | 42 (38–48) | 40 (31–47) | 41 (31–47) |
Nationality | |||
Bangladesh | 31 (20·4%) | 32 (21·1%) | 29 (19·1%) |
Egypt | 0 (0%) | 1 (0·7%) | 0 (0%) |
Ghana | 5 (3·3%) | 1 (0·7%) | 1 (0·7%) |
India | 54 (35·5%) | 63 (41·5%) | 47 (30·9%) |
Indonesia | 0 (0%) | 0 (0%) | 1 (0·7%) |
Kenya | 0 (0%) | 1 (0·7%) | 1 (0·7%) |
Nepal | 45 (29·6%) | 38 (25·0%) | 47 (30·9%) |
Pakistan | 0 (0%) | 1 (0·7%) | 3 (2·0%) |
Philippines | 7 (4·6%) | 6 (4·0%) | 6 (4·0%) |
Romania | 0 (0%) | 0 (0%) | 1 (0·7%) |
Somalia | 0 (0%) | 1 (0·7) | 0 (0%) |
Sri Lanka | 10 (6·6%) | 6 (4·0%) | 14 (9·2%) |
Sudan | 0 (0%) | 1 (0·7%) | 1 (0·7%) |
Uganda | 0 (0%) | 1 (0·7%) | 1 (0·7%) |
Baseline Ct* | 22·0 (18·4–28·0) | 23·4 (20·0–28·4) | 22·2 (19·2–26·4) |
Symptoms at enrollment | |||
Patient-reported fever | 46 (30·3%) | 51 (33·6%) | 52 (34·2%) |
Respiratory symptoms⁎⁎ | 37 (24·3%) | 36 (23·7%) | 34 (22·4%) |
Data are n (%) or median (IQR).
Ct=cycle threshold (median for all markers assessed); baseline Ct not available for two participants in hydroxychloroquine group and two participants in placebo group, thus data available for 452 of 456 randomized patients.
Respiratory symptoms: Chest pain, cough, pharyngitis, or rhinitis.